NEOS Investment Management LLC Makes New $220,000 Investment in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

NEOS Investment Management LLC purchased a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRMFree Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,442 shares of the company’s stock, valued at approximately $220,000.

Other large investors have also recently made changes to their positions in the company. AJOVista LLC purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth approximately $40,000. Wetzel Investment Advisors Inc. purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth approximately $41,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Mirum Pharmaceuticals by 447.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,394 shares of the company’s stock worth $159,000 after acquiring an additional 4,408 shares in the last quarter. Quest Partners LLC purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth approximately $194,000. Finally, Arizona State Retirement System purchased a new position in shares of Mirum Pharmaceuticals during the third quarter worth approximately $222,000.

Mirum Pharmaceuticals Trading Up 0.4 %

NASDAQ:MIRM opened at $25.07 on Friday. The company has a current ratio of 3.68, a quick ratio of 3.47 and a debt-to-equity ratio of 1.31. The firm’s fifty day simple moving average is $25.03 and its 200 day simple moving average is $27.50. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $35.56.

Mirum Pharmaceuticals (NASDAQ:MIRMGet Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.14). The firm had revenue of $69.22 million for the quarter, compared to analysts’ expectations of $69.71 million. Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative return on equity of 56.46%. Equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.39 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MIRM has been the topic of several recent analyst reports. Morgan Stanley cut their target price on shares of Mirum Pharmaceuticals from $57.00 to $53.00 and set an “overweight” rating on the stock in a report on Friday, May 10th. Citigroup raised their target price on shares of Mirum Pharmaceuticals from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, May 9th. Stifel Nicolaus initiated coverage on shares of Mirum Pharmaceuticals in a report on Wednesday, April 17th. They issued a “buy” rating and a $48.00 target price on the stock. SVB Leerink cut their target price on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a report on Monday, March 18th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $40.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 9th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $49.73.

Read Our Latest Analysis on Mirum Pharmaceuticals

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt acquired 2,000 shares of the stock in a transaction on Monday, March 18th. The stock was acquired at an average price of $25.80 per share, with a total value of $51,600.00. Following the completion of the transaction, the chief financial officer now owns 12,000 shares of the company’s stock, valued at approximately $309,600. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CFO Eric Bjerkholt purchased 2,000 shares of the stock in a transaction dated Monday, March 18th. The stock was purchased at an average price of $25.80 per share, with a total value of $51,600.00. Following the transaction, the chief financial officer now directly owns 12,000 shares in the company, valued at $309,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Saira Ramasastry sold 5,000 shares of Mirum Pharmaceuticals stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $25.68, for a total value of $128,400.00. The disclosure for this sale can be found here. Insiders own 22.87% of the company’s stock.

About Mirum Pharmaceuticals

(Free Report)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Featured Articles

Want to see what other hedge funds are holding MIRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRMFree Report).

Institutional Ownership by Quarter for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.